These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 28713563)

  • 1. Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants.
    Weitz JI; Jaffer IH; Fredenburgh JC
    F1000Res; 2017; 6():985. PubMed ID: 28713563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants.
    Weitz JI; Jaffer IH
    Pol Arch Med Wewn; 2016 Sep; 126(9):688-696. PubMed ID: 27592622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations.
    van Es N; Büller HR
    Hematology Am Soc Hematol Educ Program; 2015; 2015():125-31. PubMed ID: 26637711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism: A Systematic Review.
    Gómez-Outes A; Lecumberri R; Suárez-Gea ML; Terleira-Fernández AI; Monreal M; Vargas-Castrillón E
    J Cardiovasc Pharmacol Ther; 2015 Sep; 20(5):490-500. PubMed ID: 25802423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct oral anticoagulants: Current indications and unmet needs in the treatment of venous thromboembolism.
    Bertoletti L; Ollier E; Duvillard C; Delavenne X; Beyens MN; De Magalhaes E; Bellet F; Basset T; Mismetti P; Laporte S
    Pharmacol Res; 2017 Apr; 118():33-42. PubMed ID: 27350265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
    Beyer-Westendorf J; Ageno W
    Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.
    Wu C; Alotaibi GS; Alsaleh K; Linkins LA; McMurtry MS
    Thromb Res; 2015 Feb; 135(2):243-8. PubMed ID: 25488466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran.
    Leung TS; Law EH
    Drug Des Devel Ther; 2015; 9():3557-69. PubMed ID: 26185422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New anticoagulants in the management of venous thromboembolism in women.
    Piovella F; Irina Iosub D
    Thromb Res; 2015 Feb; 135 Suppl 1():S5-7. PubMed ID: 25903537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism.
    Voigtlaender M; Langer F
    Hamostaseologie; 2017; 37(4):241-255. PubMed ID: 29582927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Direct Oral Anticoagulants in the Treatment of Cancer-Associated Venous Thromboembolism: Review by Middle East and North African Experts.
    Bazarbashi S; El Zawahry HM; Owaidah T; AlBader MA; Warsi A; Marashi M; Dawoud E; Jaafar H; Sholkamy SM; Haddad F; Cohen AT
    J Blood Med; 2024; 15():171-189. PubMed ID: 38686358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment.
    Burnett AE; Mahan CE; Vazquez SR; Oertel LB; Garcia DA; Ansell J
    J Thromb Thrombolysis; 2016 Jan; 41(1):206-32. PubMed ID: 26780747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
    Hillis C; Crowther MA
    Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Novel Oral Anticoagulants for Acute Venous Thromboembolism: Is Warfarin Dead?
    Cohen AT; Granziera S; Veronese N; Zoppellaro G
    Semin Respir Crit Care Med; 2017 Feb; 38(1):29-39. PubMed ID: 28208196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term benefits of preventing venous thromboembolic events.
    Cohen AT
    Curr Med Res Opin; 2012 Jun; 28(6):877-89. PubMed ID: 22533680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of nonmajor bleeding upon use of direct oral anticoagulants for preventing and treating venous thromboembolism: A network meta-analysis.
    Chen J; Lv M; Jiang S; Wu S; Xu W; Qian J; Zeng Z; Chen M; Fang Z; Zhang J
    Vasc Med; 2022 Dec; 27(6):565-573. PubMed ID: 36065470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing pulmonary embolism from presentation to extended treatment.
    Cohen AT; Dobromirski M; Gurwith MM
    Thromb Res; 2014 Feb; 133(2):139-48. PubMed ID: 24182642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct Oral Anticoagulants and Travel-related Venous Thromboembolism.
    Chamnanchanunt S; Rojnuckarin P
    Open Med (Wars); 2018; 13():575-582. PubMed ID: 30519635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New oral anticoagulants for the treatment of venous thromboembolism.
    Agnelli G; Becattini C; Franco L
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.